Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design.
about
Mimotope vaccination--from allergy to cancerA novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2.High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells.Characterizing complex polysera produced by antigen-specific immunization through the use of affinity-selected mimotopesRegulation of the G2/M phase of the cell cycle by sperm associated antigen 8 (SPAG8) protein.Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cellsApplying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine designGeneration and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.Generation and characterization of chimeric antibodies against NS3, NS4, NS5, and core antigens of hepatitis C virusAnti-HER2 vaccines: new prospects for breast cancer therapyAntibody phage display libraries: contributions to oncology.Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD).Mimotope vaccines: epitope mimics induce anti-cancer antibodiesHighly efficient selection of epitope specific antibody through competitive yeast display library sortingSynthetic peptides as cancer vaccines.High throughput functional epitope mapping: revisiting phage display platform to scan target antigen surface.Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyCombining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth.Cellulose-bound peptide arrays: preparation and applications.Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis.Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study.In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells.Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.A novel recombinant anti-epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model.Interface Peptides
P2860
Q24608624-E755C1FE-C810-4183-B569-D398D9A43528Q33208837-A0144526-BA0E-4ED9-AA53-4674CA3FACB9Q33209339-0A5B56B6-998C-4990-8276-A9572A5BF5A8Q33434406-10B0A934-8DD1-43FD-B6A4-9D872FE7A893Q33472792-480214A6-862F-4C7F-82BD-80AB4DA23D01Q33587034-F6DCA775-77E7-46AD-B51D-A148E4524CBFQ33645792-229A7D16-8C4E-4BB4-A77E-9C50B05F60EDQ33743491-301EF25C-2E25-44D6-829A-5E1D14C4CF93Q33907971-4E3DDB75-2EF5-4471-913A-3C49E9B91E84Q33909206-69F8061E-8D17-49AD-B871-2528F665283FQ34105959-327ECBB9-D2E3-4C9A-B795-49D314F9807CQ34323991-00BEBCFF-4E2E-49ED-AC04-D1286A6A9AB5Q34597809-128FBEBA-DEB4-4E9D-A5F8-3DF293DB5B0BQ34650345-E7AE4D0C-EC52-4DA0-A331-0E0D9E3D7457Q34655015-2EE7B453-D7EC-4A36-8E50-EDBE12E873FDQ34772027-E01DC97E-CE1F-477C-82CA-CAF611801F8CQ34972916-8C77C52B-16A1-461B-83D7-29C1B0965E7FQ35498790-F912778C-F528-4625-BDFD-10E28FF1278DQ35987717-809B34D1-B08C-429B-907B-CBE1C047D2A8Q36116250-C46D411A-6250-4253-AB90-66B32A3526C3Q36785573-F365C9E8-1B3B-4AFC-A509-33B14DF5CAA4Q37024675-E79D529D-F258-476B-B1EF-07F66D316A7CQ37117664-B1777BC8-7FC6-4366-8D25-56A68811D964Q38076053-CE3870BB-1B44-4571-87E4-02732F3F6383Q38873050-E1886C87-1AE6-475F-93D5-483986B1BCA4Q39042958-9897338B-0C8C-4A7A-9609-F648C4566FADQ40351380-185BD6D2-BF60-4FEB-B270-2C83CC5BEC42Q45858638-491A80B9-AEA7-4855-B24D-A405D3BC98D0Q47576243-8FD8F4B2-5896-4345-9964-1BE08BD0B7D0Q57721879-B7548C0A-87DB-454C-871D-E78EB468DFEC
P2860
Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Identification of epitope regi ...... plications for vaccine design.
@ast
Identification of epitope regi ...... plications for vaccine design.
@en
type
label
Identification of epitope regi ...... plications for vaccine design.
@ast
Identification of epitope regi ...... plications for vaccine design.
@en
prefLabel
Identification of epitope regi ...... plications for vaccine design.
@ast
Identification of epitope regi ...... plications for vaccine design.
@en
P2093
P1476
Identification of epitope regi ...... plications for vaccine design.
@en
P2093
P304
P356
10.4049/JIMMUNOL.166.8.5271
P407
P50
P577
2001-04-01T00:00:00Z